roche holding ag firm to appeal ruling on tarceva by u k panel roche holding ag said it will appeal a decision by the u k health advisory agency to not reimburse patients with lung cancer for the drug tarceva the decision by the u k national institute for health and clinical excellence follows a november recommendation against making tarceva available in england and wales on the state funded national health service on the basis that the swiss pharmaceutical firms drug doesnt provide better overall survival or progression free survival than less expensive treatments 
